Sun Sep 15 10:20:59 UTC 2024: ## Quest Partners Boosts Stake in Tandem Diabetes Care, Analysts Remain Bullish
**New York, NY** – Quest Partners LLC, a prominent institutional investor, significantly increased its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the second quarter, according to the firm’s recent Form 13F filing. The investment firm acquired an additional 5,234 shares, boosting its total ownership to 5,892 shares, representing a 795.4% increase in their stake.
Quest Partners’ move is reflective of a growing interest in TNDM, with several other investors also adjusting their positions in the medical device company. ORG Partners LLC entered a new position in the second quarter, while Headlands Technologies LLC acquired a new stake in the first quarter. MCF Advisors LLC and Signaturefd LLC both increased their holdings during the respective quarters. Quadrant Capital Group LLC also significantly boosted its stake in the fourth quarter.
These investments follow a string of positive analyst reports on Tandem Diabetes Care. Barclays recently raised its target price to $58.00, maintaining an “overweight” rating. Canaccord Genuity Group initiated coverage with a “buy” rating and a $57.00 price target. Lake Street Capital and Stifel Nicolaus also increased their price targets, highlighting the bullish sentiment surrounding the company. While Morgan Stanley initiated coverage with an “equal weight” rating and a $45.00 price target, the overall consensus among analysts remains positive, with a “Moderate Buy” rating and an average price target of $54.36.
Tandem Diabetes Care’s flagship product, the t:slim X2 insulin delivery system, is a key driver of the company’s success. This pump platform offers users a convenient way to manage insulin delivery and provides continuous glucose monitoring information directly on the pump screen. The company’s Tandem Mobi insulin pump, an automated insulin delivery system, is also gaining traction in the market.
While the stock opened at $43.97 on Friday, the company’s strong fundamentals and positive outlook suggest it has the potential to continue its upward trajectory. With a debt-to-equity ratio of 1.31, a current ratio of 3.05, and a quick ratio of 2.38, the company appears well-positioned to navigate future challenges and capitalize on its growing market share.
**Investors seeking further insights into Tandem Diabetes Care’s performance can access the latest 13F filings and insider trades through HoldingsChannel.com.**
**Disclaimer:** This news article is for informational purposes only and does not constitute investment advice.
First Piper 